JScreen, a national non-profit public health initiative dedicated to preventing genetic diseases and hereditary cancer, educates communities across the United States on the importance of genetic screening for personal and family health. JScreen announced their support for National Cancer Control Month in April.

Alnylam Pharmaceuticals reported positive results for the ILLUMINATE-B Phase III clinical trial evaluating the RNAi therapeutic lumasiran in young children with primary hyperoxaluria type 1 (PH1).